1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Adrenoleukodystrophy - Drugs In Development, 2022, provides an overview of the Adrenoleukodystrophy (Genetic Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Adrenoleukodystrophy is a disorder that occurs most often in males. It mainly affects the nervous system and the adrenal glands, which are small glands located on top of each kidney. Abetalipoproteinemia is also a kind of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Bassen-Kornzweig syndrome is a rare disease passed down through families in which a person is unable to fully absorb dietary fats through the intestines. The disease is caused by a defect in gene that tells the body to create lipoproteins. It is sympotomized by curvature of spine, muscle weakness, decrease of vision over time. Treatment involves large doses of vitamin supplements containing fat-soluble vitamins.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Adrenoleukodystrophy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Adrenoleukodystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Adrenoleukodystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 2, 4, 4, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 1 and 2 molecules, respectively.
Adrenoleukodystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Adrenoleukodystrophy (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Adrenoleukodystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Adrenoleukodystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Adrenoleukodystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Adrenoleukodystrophy (Genetic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Adrenoleukodystrophy (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Adrenoleukodystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Overview
- Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Companies Involved in Therapeutics Development
- Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Drug Profiles
- Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Dormant Projects
- Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Discontinued Products
- Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by Apteeus SAS, 2022
- Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by Ashvattha Therapeutics LLC, 2022
- Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by Autobahn Therapeutics Inc, 2022
- Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by bluebird bio Inc, 2022
- Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by Celularity Inc, 2022
- Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by Imstem Biotechnology Inc, 2022
- Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by MedDay SA, 2022
- Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by Minoryx Therapeutics sl, 2022
- Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by Orpheris Inc, 2022
- Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by Poxel SA, 2022
- Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by ReceptoPharm Inc, 2022
- Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by SwanBio Therapeutics Ltd, 2022
- Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by Vigil Neuroscience Inc, 2022
- Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Pipeline by Viking Therapeutics Inc, 2022
- Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Dormant Projects, 2022
- Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) - Discontinued Products, 2022
- Number of Products under Development for Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Apteeus SAS
- Ashvattha Therapeutics LLC
- Autobahn Therapeutics Inc
- bluebird bio Inc
- Celularity Inc
- Imstem Biotechnology Inc
- MedDay SA
- Minoryx Therapeutics sl
- Orpheris Inc
- Poxel SA
- ReceptoPharm Inc
- SwanBio Therapeutics Ltd
- Vigil Neuroscience Inc
- Viking Therapeutics Inc
